Determinants of antithrombin consumption in cardiac operations requiring cardiopulmonary bypass

Abstract

Antithrombin (AT) is a natural anticoagulant that is consumed during cardiac operations with cardiopulmonary bypass (CPB). This study is an observational trial aimed at identifying the factors determining the magnitude of the AT consumption during cardiac operations. Two hundred and fifty consecutive adult patients undergoing cardiac operations with CPB were admitted to the study. Preoperative and intraoperative variables were tested with respect to their role in determining AT activity at the end of the operation. At a univariate analysis, eight predictors of AT activity at the end of the operation have been identified: preoperative AT activity; age; diabetes on medication; preoperative haematocrit value; preoperative dialysis; combined operation; CPB duration; lowest temperature on CPB. A multivariate predictive model was created, and five factors remained as independent predictors of AT activity at the end of the operation: preoperative AT activity (p = 0.001); age (p = 0.015); combined operation (p = 0.014); diabetes (p = 0.013) and CPB duration (p = 0.001). On this basis, predictive tables of AT consumption have been established for different combinations of risk factors.

Get full access to this article

View all access options for this article.

References

Turner-Gomes SO , Andrew M , Coles J , Trusler GA , Williams WG , Rabinovitch M. Abnormalities in von Willebrand factor and antithrombin III after cardiopulmonary bypass operations for congenital heart disease . J Thorac Cardiovasc Surg 1992; 103: 87-97 .

Hashimoto K , Yamagishi M , Sasaki T , Nakano M , Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with sub-clinical plasma coagulation . Ann Thorac Surg 1994; 58: 799-805 .

Ranucci M , Cazzaniga A , Soro G , Isgro` G , Frigiola A , Menicanti L. The antithrombin III-saving effect of reduced systemic heparinization and heparin-coated circuits . J Cardiothorac Vasc Anesth 2002; 16: 316-320 .

Ranucci M. Antithrombin III. Key factor in extracorporeal circulation . Minerva Anestesiol 2002; 68: 454-457 .

Ranucci M , Isgro` G , Cazzaniga A , Soro G , Menicanti L , Frigiola A. Predictors for heparin resistance in patients undergoing coronary artery bypass grafting . Perfusion 1999; 14: 437-442 .

Ranucci M , Isgro` G , Cazzaniga A et al. Different patterns of heparin resistance: therapeutic implications . Perfusion 2002; 17: 199-204 .

Lemmer JH , Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery . J Thorac Cardiovasc Surg 2002; 123: 213-217 .

Spiess BD. Heparin: beyond an anticoagulant. In Spiess BD ed. The relationship between coagulation, inflammation and endothelium-a pyramid towards outcome. Baltimore, MD: Lippincott Williams & Wilkins , 2000: 169-190.

Bull BS , Korpman RA , Huse WM , Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols . J Thorac Cardiovasc Surg 1975; 69: 685-689 .

10.

Conlan MG , Folsom AR , Finch A et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis . Thromb Hae-most 1993; 70: 380-385 .

11.

Carr ME. Diabetes mellitus: a hypercoagulable state . J Diabetes Complications 2001; 15: 44-54 .

12.

Wendel HP , Eckstein FS , Fink E et al. Increased coagulation and bradykinin-release in shed pleural blood during cardiac surgery . Immunopharmacology 1999; 44: 119-122 .